Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 69

1.

Endogenous expression of Hras(G12V) induces developmental defects and neoplasms with copy number imbalances of the oncogene.

Chen X, Mitsutake N, LaPerle K, Akeno N, Zanzonico P, Longo VA, Mitsutake S, Kimura ET, Geiger H, Santos E, Wendel HG, Franco A, Knauf JA, Fagin JA.

Proc Natl Acad Sci U S A. 2009 May 12;106(19):7979-84. doi: 10.1073/pnas.0900343106. Epub 2009 Apr 29.

2.

Mice with an Oncogenic HRAS Mutation are Resistant to High-Fat Diet-Induced Obesity and Exhibit Impaired Hepatic Energy Homeostasis.

Oba D, Inoue SI, Miyagawa-Tomita S, Nakashima Y, Niihori T, Yamaguchi S, Matsubara Y, Aoki Y.

EBioMedicine. 2018 Jan;27:138-150. doi: 10.1016/j.ebiom.2017.11.029. Epub 2017 Dec 6.

3.

Mutant Hras(G12V) and Kras(G12D) have overlapping, but non-identical effects on hepatocyte growth and transformation frequency in transgenic mice.

Figueiredo ML, Stein TJ, Jochem A, Sandgren EP.

Liver Int. 2012 Apr;32(4):582-91. doi: 10.1111/j.1478-3231.2011.02732.x. Epub 2012 Jan 3.

4.

Interactions between wild-type and mutant Ras genes in lung and skin carcinogenesis.

To MD, Rosario RD, Westcott PM, Banta KL, Balmain A.

Oncogene. 2013 Aug 22;32(34):4028-33. doi: 10.1038/onc.2012.404. Epub 2012 Sep 3.

5.

H-Ras and K-Ras Oncoproteins Induce Different Tumor Spectra When Driven by the Same Regulatory Sequences.

Drosten M, Simón-Carrasco L, Hernández-Porras I, Lechuga CG, Blasco MT, Jacob HK, Fabbiano S, Potenza N, Bustelo XR, Guerra C, Barbacid M.

Cancer Res. 2017 Feb 1;77(3):707-718. doi: 10.1158/0008-5472.CAN-16-2925. Epub 2016 Nov 21.

6.

C4ST-1/CHST11-controlled chondroitin sulfation interferes with oncogenic HRAS signaling in Costello syndrome.

Klüppel M, Samavarchi-Tehrani P, Liu K, Wrana JL, Hinek A.

Eur J Hum Genet. 2012 Aug;20(8):870-7. doi: 10.1038/ejhg.2012.12. Epub 2012 Feb 8.

7.

Reduced HRAS G12V-Driven Tumorigenesis of Cell Lines Expressing KRAS C118S.

Huang L, Counter CM.

PLoS One. 2015 Apr 22;10(4):e0123918. doi: 10.1371/journal.pone.0123918. eCollection 2015.

8.

Low incidence of oncogenic EGFR, HRAS, and KRAS mutations in seborrheic keratosis.

Georgieva IA, Mauerer A, Groesser L, Herschberger E, Aslanidis C, Dietmaier W, Landthaler M, Hafner C.

Am J Dermatopathol. 2014 Aug;36(8):635-42. doi: 10.1097/DAD.0b013e31828c0542.

PMID:
23739246
9.

HRAS mutations in Costello syndrome: detection of constitutional activating mutations in codon 12 and 13 and loss of wild-type allele in malignancy.

Estep AL, Tidyman WE, Teitell MA, Cotter PD, Rauen KA.

Am J Med Genet A. 2006 Jan 1;140(1):8-16.

PMID:
16372351
10.

A critical role of MYC for transformation of human cells by HPV16 E6E7 and oncogenic HRAS.

Narisawa-Saito M, Inagawa Y, Yoshimatsu Y, Haga K, Tanaka K, Egawa N, Ohno S, Ichikawa H, Yugawa T, Fujita M, Kiyono T.

Carcinogenesis. 2012 Apr;33(4):910-7. doi: 10.1093/carcin/bgs104. Epub 2012 Feb 15.

PMID:
22345164
11.

HRAS mutations in bladder cancer at an early age and the possible association with the Costello Syndrome.

Beukers W, Hercegovac A, Zwarthoff EC.

Eur J Hum Genet. 2014 Jun;22(6):837-9. doi: 10.1038/ejhg.2013.251. Epub 2013 Oct 30.

12.

Dysregulation of astrocyte extracellular signaling in Costello syndrome.

Krencik R, Hokanson KC, Narayan AR, Dvornik J, Rooney GE, Rauen KA, Weiss LA, Rowitch DH, Ullian EM.

Sci Transl Med. 2015 May 6;7(286):286ra66. doi: 10.1126/scitranslmed.aaa5645.

13.

Oncogenic KRAS impairs EGFR antibodies' efficiency by C/EBPβ-dependent suppression of EGFR expression.

Derer S, Berger S, Schlaeth M, Schneider-Merck T, Klausz K, Lohse S, Overdijk MB, Dechant M, Kellner C, Nagelmeier I, Scheel AH, Lammerts van Bueren JJ, van de Winkel JG, Parren PW, Peipp M, Valerius T.

Neoplasia. 2012 Mar;14(3):190-205.

14.

HRAS mutants identified in Costello syndrome patients can induce cellular senescence: possible implications for the pathogenesis of Costello syndrome.

Niihori T, Aoki Y, Okamoto N, Kurosawa K, Ohashi H, Mizuno S, Kawame H, Inazawa J, Ohura T, Arai H, Nabatame S, Kikuchi K, Kuroki Y, Miura M, Tanaka T, Ohtake A, Omori I, Ihara K, Mabe H, Watanabe K, Niijima S, Okano E, Numabe H, Matsubara Y.

J Hum Genet. 2011 Oct;56(10):707-15. doi: 10.1038/jhg.2011.85. Epub 2011 Aug 18.

PMID:
21850009
15.

Mechanisms underlying cognitive deficits in a mouse model for Costello Syndrome are distinct from other RASopathy mouse models.

Schreiber J, Grimbergen LA, Overwater I, Vaart TV, Stedehouder J, Schuhmacher AJ, Guerra C, Kushner SA, Jaarsma D, Elgersma Y.

Sci Rep. 2017 Apr 28;7(1):1256. doi: 10.1038/s41598-017-01218-0.

16.

An attenuated phenotype of Costello syndrome in three unrelated individuals with a HRAS c.179G>A (p.Gly60Asp) mutation correlates with uncommon functional consequences.

Gripp KW, Sol-Church K, Smpokou P, Graham GE, Stevenson DA, Hanson H, Viskochil DH, Baker LC, Russo B, Gardner N, Stabley DL, Kolbe V, Rosenberger G.

Am J Med Genet A. 2015 Sep;167A(9):2085-97. doi: 10.1002/ajmg.a.37128. Epub 2015 Apr 25.

17.

RAS/PI3K crosstalk and cetuximab resistance in head and neck squamous cell carcinoma.

Rampias T, Giagini A, Siolos S, Matsuzaki H, Sasaki C, Scorilas A, Psyrri A.

Clin Cancer Res. 2014 Jun 1;20(11):2933-46. doi: 10.1158/1078-0432.CCR-13-2721. Epub 2014 Apr 2.

19.

Uniparental disomy at chromosome 11p15.5 followed by HRAS mutations in embryonal rhabdomyosarcoma: lessons from Costello syndrome.

Kratz CP, Steinemann D, Niemeyer CM, Schlegelberger B, Koscielniak E, Kontny U, Zenker M.

Hum Mol Genet. 2007 Feb 15;16(4):374-9. Epub 2006 Dec 12. Erratum in: Hum Mol Genet. 2007 Nov 15;16(22):2781.

PMID:
17164262
20.

Functional analysis of a duplication (p.E63_D69dup) in the switch II region of HRAS: new aspects of the molecular pathogenesis underlying Costello syndrome.

Lorenz S, Lissewski C, Simsek-Kiper PO, Alanay Y, Boduroglu K, Zenker M, Rosenberger G.

Hum Mol Genet. 2013 Apr 15;22(8):1643-53. doi: 10.1093/hmg/ddt014. Epub 2013 Jan 17.

PMID:
23335589

Supplemental Content

Support Center